Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Jolain
B
B
Pettitt
D
D
D003327:Coronary Disease / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents / Q000191:economics* / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents